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ABSTRACT 
Ottavia Zattra: Obesity-Induced Mast Cell Infiltration and Activation in Normal Mammary Tissue and 
Claudin-Low Breast Tumors  
(Under the direction of Dr. Liza Makowski Hayes) 
Obesity is among the most prevalent conditions worldwide: in the United States alone, more than 60% of 
the population is either overweight or obese. The condition remains a well-known modifiable risk factor 
for multiple diseases, including cancer. Obesity is characterized by a low-grade smoldering inflammatory 
state, which both induces and is sustained by many polarized, pro-inflammatory immune cells. Recent 
studies have also highlighted the role of the immune system in the genesis and progression of cancer, with 
many immune cell lineages working to promote angiogenesis, tumor growth and metastasis. One of these 
immune cells lineages are mast cells (MCs), a type of long-lived myeloid stem cell-derived granulocyte 
that are traditionally known for their role in the allergic response known as anaphylaxis, but also mediate 
wound healing and vessel formation. MCs play a crucial role in the tumor microenvironment, by secreting 
proteases, cytokines and other factors that promote angiogenesis, extracellular matrix degradation and 
metastasis. Previous studies have reported increased mast cell presence in visceral adipose tissue in obesity. 
Thus, this study investigated whether obesity promotes mast cell infiltration into and activation within 
normal mammary tissue and claudin-low breast tumors, an aggressive triple negative subtype of breast 
cancer. To test our hypotheses, we utilized C57BL/6J and FVB/NJ mouse strains. Female C57BL/6J mice 
were weaned onto either low fat (LFD, 10% kcal from fat) or high fat (HFD, 60% kcal from fat) diet at 3 
weeks of age. At 13 weeks of age, C57BL/6J mice underwent syngeneic orthotopic transplant of M-Wnt 
claudin-low breast cancer cells into their mammary fat pad. In addition, female FVB/NJ mice were 
randomized to either LFD or HFD at 8 weeks of age; at 13 weeks of age, mice in a Diet Switch (DS) group 
were also transitioned from HFD to LFD to induce weight loss prior to tumor injection. FVB/NJ mice 
underwent syngeneic orthotopic transplant of C3-Tag-luc claudin-low breast cancer cells into their 
mammary fat pad at 18 weeks of age. We sought to measure mast cell infiltration and activation through 
histological quantification of mast cell density (cells/mm2), and through quantification of Tryptase β-2 
mRNA expression levels, respectively. Relative to tumors, higher mast cell density, as well as higher 
Tryptase β-2 mRNA expression, was observed in normal mammary of C57BL/6J mice. Importantly, in 
C57BL/6J mice, higher mRNA expression was also observed across tissues in HFD-fed as compared to 
LFD-fed mice by two-way ANOVA. In FVB/NJ mice, higher MC density was observed in tumors as 
compared to normal mammary. Furthermore, higher Tryptase expression was observed in normal mammary 
tissue upon conditions of obesity, and was significantly reversed with weight loss before tumor 
development. In summary, these results indicate that low and high fat diets have differential effects on 
murine models, including body weight and body composition, and that high fat diet may influence mast 
cell activation in normal mammary tissue, independently of mast cell density. This pilot study offers 
insights into a potential role of obesity in modulating activation of mast cells, emphasizing the need for 
future investigation into mast cells as mediators of the relationship between obesity and breast cancer risk 
or progression.  
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STUDY AIMS AND HYPOTHESIS  
Several recent studies have highlighted a strong and worrisome correlation between high body mass index 
(BMI) and cancer malignancy, with multiple immune cell lineages found to play a significant role in the 
development of both obesity and cancer. Mast cells (MCs), a type of myeloid stem cell-derived granulocyte 
that are classified as part of the innate immune system, are one of these lineages. In the tumor 
microenvironment, MCs were reported to secrete angiogenic signals, growth factors and proteases that 
support tumor development and promote progression and metastasis [1]. In many cancers, high MC density 
is indicative of adverse clinical outcomes [2]. In obesity, MC accumulation is observed within a number of 
body fat depots, including visceral (epididymal) and subcutaneous fat pads [3, 4], with MCs sustaining a 
pro-inflammatory and angiogenic extracellular milieu [4]. Importantly, to date, there have been no studies 
addressing the influence of obesity on mast cells in the normal breast or breast cancer, leaving a gap that 
needs to be studied to better understand the underlying mechanisms of obesity-associated breast cancer. 
Thus, the enclosed studies investigated obesity-induced mast cell infiltration of normal mammary tissue 
and triple negative breast tumors in two lean and obese pre-clinical murine models. We hypothesized that 
obesity influences mast cell infiltration into and activation within mammary adipose tissue. We further 
hypothesized that weight or body composition status influences tumor mast cell infiltration into and 
activation within claudin-low breast tumors. 
 
To study these hypotheses, we used two orthotopic transplant models of claudin-low breast cancer [5] 
implanted into adult female mice of C57BL/6J and FVB/NJ backgrounds. Prior to injection of cells to create 
tumors, mice were exposed to low fat (LFD, 10% kcal from fat) and high fat (HFD, 60% kcal from fat) 
diets in order to generate lean and obese animals, respectively. A portion of the FVB/NJ obese mouse cohort 
underwent a diet switch (DS), wherein mice were transitioned from HFD to LFD to induce weight loss 
before tumor cell injection. Our study was conducted by completing the following two aims. In Aim 1, we 
 7 
investigated the correlation between obesity and mast cell density and activation in mammary adipose 
tissue. In Aim 2, we examined the same relationship within the tumor mass itself.   
 
 
SPECIFIC AIMS 
Aim 1: To determine if obesity alters mast cell infiltration and activation in the mouse mammary fat 
pad 
HYPOTHESIS: Adipose MC density will parallel weight gain and weight loss. Mice fed HFD (60% kcal 
from fat) will present higher MC infiltration and activation within their normal (uninjected) mammary fat 
pad than mice fed LFD (10% kcal from fat) or induced to lose weight by DS to LFD following a period of 
obesity. Higher MC infiltration will be observed as higher MC density (cells/mm2) in HFD vs. LFD/DS 
normal mammary fat depots, while higher MC activation will be observed as increased mRNA expression 
of MC-specific Tryptase ß-2 in obese mammary tissue. 
RATIONALE: Obesity has been associated with increased MC density in a number of adipose depots, 
including the epididymal and other visceral fat pads in male mice, and visceral and subcutaneous fat pads 
in humans [3, 4, 6], but MC accumulation in normal breast tissue has not been extensively studied. The 
breast is a major adipose depot in the female body. Previous studies by our group and others have shown 
that, upon conditions of obesity, this depot is subject to infiltration by immune cells, such as macrophages 
[7]; thus, we posit that obesity might equally induce mast cell infiltration of mammary adipose tissue. 
Moreover, studies have shown that MC-derived tryptases promote the development of obesity-induced 
fibrosis in obese adipose, a phenomenon that impairs the structure of fat depots - leading to severe tissue 
malfunctioning - but that can also be reversed with anti-tryptase antibody treatment [8]. Thus elevated 
tryptase levels in obese mammary adipose tissue will be used as a proxy measure of MC presence and 
activation. 
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EXPERIMENTAL DESIGN: 
C57BL/6J mouse cohort: 
• Weaned mice onto LFD and HFD at 3 weeks of age  
• At 13 weeks of age, performed orthotopic transplant of claudin-low M-Wnt breast cancer cell line 
into 4th (abdominal) left mammary fat pad 
• Monitored weekly for tumor growth by digital caliper  
• Collected tumor (tumor length 1±0.25 cm in any direction) and contralateral uninjected normal 
mammary fat pad at sacrifice  
• Established a subset of two mice groups exposed to LFD (n=5) and HFD (n=5) 
• Used Toluidine Blue staining to assess MC content (cells/mm2) in normal mammary in both LFD- 
and HFD-fed groups 
• Assessed tissue MC activation through quantitative gene expression analysis of MC-specific 
Tryptase β-2 mRNA (qPCR) 
FVB/NJ mouse cohort: 
• Randomized mice onto LFD and HFD at 8 weeks of age 
• At 13 weeks, transferred mice in the DS cohort from HFD to LFD 
• At 18 weeks, performed syngeneic orthotopic transplant of C3-Tag-luc claudin-low cancer cell line 
obtained from lean C3(1)-TAg mice into the left 4th mammary fat pad  
• Monitored thrice weekly for tumor growth by digital caliper 
• Collected tumor and contralateral normal mammary fat pad at sacrifice, 3 weeks after injection 
• Established a subset of three mouse groups exposed to LFD (n=7), HFD (n=8) and DS (n=8) 
• Used Toluidine Blue staining to assess MC content in normal mammary in LFD-fed, HFD-fed and 
DS groups 
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• Assessed tissue MC activation through quantitative gene expression analysis of MC-specific 
tryptase β-2 mRNA (qPCR) 
 
Aim 2: To determine if obesity alters mast cell infiltration and activation in claudin-low breast tumors 
HYPOTHESIS: Mice fed HFD group (60% kcal from fat) will present higher MC infiltration in their 
breast tumor mass than mice fed LFD (10% kcal from fat) or mice in the DS group (60%  10% kcal from 
fat). Higher MC infiltration will be observed as higher MC density (cells/mm2) in obese tumors, while 
higher MC activation will be observed as increased mRNA expression of MC-specific Tryptase β-2 in obese 
tumors. 
RATIONALE: MCs are one of the immune cell lineages that are polarized within the tumor 
microenvironment toward a pro-tumoral phenotype [1]. MCs support tumor growth through the secretion 
of angiogenic factors and proteases, and many MC-derived inflammatory factors, such as tryptase β-2, play 
a critical role in the promotion of angiogenesis and metastasis [9, 10]. Obesity remains a strong risk factor 
in the development of breast cancer, especially triple-negative types [11-13]. As an endocrine organ, 
adipose tissue is increasingly being implicated in the activation process of immune cells toward a pro-
inflammatory and pro-tumoral phenotype [14]. Thus, it is plausible that obesity may support MC presence 
or activation as a contributor to the establishment of an extracellular milieu favorable to tumor growth.  
EXPERIMENTAL DESIGN: 
C57BL/6J and FVB/NJ mouse cohorts: 
• Used Toluidine Blue staining to assess MC content (cells/mm2) in tumors of LFD, HFD and DS 
groups  
• Assessed tissue MC activation through quantitative gene expression analysis of MC-specific 
tryptase β-2 mRNA (qPCR) 
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Figure 1. Diet and Orthotopic Transplant Study Design for C57BL/6J mice. Female C57BL/6J mice 
were weaned onto LFD (10% kcal from fat, n=5) or a micronutrient- and sucrose-matched HFD (60% kcal 
from fat, n=5) at 3 weeks of age. At 13 weeks of age, mice underwent syngeneic orthotopic transplant of 
M-Wnt cancer cell line into the left 4th mammary fat pad. Tumor growth was monitored weekly, and 
detected tumors were measured with calipers every two days. Mice were sacrificed at tumor diameter of 
1±0.25 cm in any direction. Tumors and contralateral, uninjected mammary fat pads were collected at 
sacrifice. 
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Figure 2. Diet and Orthotopic Transplant Study Design for FVB/NJ mice. Female wild-type FVB/NJ 
mice were started onto LFD (10% kcal from fat, n=7) and HFD (60% kcal from fat, n=8) at 8 weeks of age. 
At 13 weeks of age, mice in the DS cohort (n=8) were transferred from HFD to LFD to induce weight loss. 
At 18 weeks, mice underwent syngeneic orthotopic transplant of the claudin-low C3-Tag-luc cancer cell 
line into the left 4th mammary fat pad. Tumor growth was monitored thrice weekly. All mice were sacrificed 
3 weeks after tumor cell injection, at 21 weeks of age. Tumor and contralateral uninjected mammary fat 
pads were collected at sacrifice.  
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INTRODUCTION  
Obesity levels in the United States have reached epidemic proportions. According to the Centers 
for Disease Control and Prevention (CDC), in 2014 more than one-third of U.S. adults and 17% of 
adolescents were obese, with no U.S. state experiencing a rate below 20% [15] The rising prevalence of 
obesity is a major public health concern, as the condition is a renowned risk factor for a variety of chronic 
illnesses, most notably hypertension, cardiovascular disease, stroke, and type-2 diabetes [16].  
Importantly, recent epidemiological studies have also identified obesity as a significant risk factor 
for multiple cancer types, including esophagus, colon and rectum, endometrial and breast malignancies [17] 
Indeed, excess adiposity contributes to approximately 20% of all cancers [17], with a total health burden 
that will soon surpass that of cigarette smoking [18]. In women, obesity is strongly associated with breast 
cancer, with high BMI linked to greater incidences, higher rates of lymph node positivity and poorer 
prognosis [11-13].   
The Carolina Breast Cancer Study conducted in 2006 by Carey et al. characterized breast cancer 
subtypes on the basis of their molecular presentation of estrogen receptors (ER), progesterone receptors 
(PR) and human epidermal growth factor receptor 2 (HER2). The four main breast cancer characterizations 
that resulted from the study were: Luminal A (ER+, PR+, HER2-), Luminal B (ER+, PR+, HER2+), HER2- 
enriched (ER-, PR-, HER2+), and triple-negative (ER-, PR-, HER2-) breast cancers [19].  
Among the four subtypes, triple-negative breast cancers (TNBCs) account for approximately 10-
20% of invasive breast cancer incidence [20, 21], and disproportionately affect women who are of African 
ancestry, premenopausal and below the age of 40, have a family history of breast cancer and/or present a 
BRCA1 mutation [19, 20, 22]. An analysis of 2544 invasive breast cancer cases from two prospective 
studies also found that a TNBC diagnosis is more likely associated with overweight and obese BMIs [23]. 
TNBCs display a highly aggressive phenotype, with peak recurrence within 3 years of diagnosis [20], 
greater incidence of metastasis, poorer prognosis and lower 5-year survival rates relative to other breast 
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cancer subtypes [19]. Because of their molecular profile, no biologically targeted therapy is currently 
available for the treatment of TNBCs, a fact that makes clinical management of these cancers particularly 
challenging.  
A new molecular class of TNBC, known as claudin-low, was recently described based on extensive 
genomic profiling of breast cancer patient biopsies [24, 25]. Claudin-low breast cancers are characterized 
by a low genetic expression of tight junction proteins claudin 3, 4 and 7, as well as low calcium-dependent 
cell-cell adhesion glycoprotein E-cadherin [21]. In comparison with more widely known basal-like breast 
cancer subtype, claudin-low tumors are slower-cycling, thus showing reduced RNA levels of proliferation 
marker Ki67, but present increased expression of immune response, angiogenesis, and cell migration genes 
[21]. In particular, due to the tendency for extensive immune response, we have utilized claudin-low  breast 
cancers in our studies of obesity-mediated immune cell presence and activation. 
While a cancer’s ability to survive and proliferate is often attributed to genetic aberrations of the 
cancer cell itself, studies in the last few decades have highlighted the pivotal role that tumor-driven 
modulations of physiological processes, both in the surrounding microenvironment and at a systemic level, 
have in the process of tumorigenesis. In particular, the development of malignancy is characterized by a 
profound suppression of immunosurveillance, with tumor cells obstructing immune system-driven 
antitumoral responses [26]. This process not only manifests as changes in cancer cells that make them less 
recognizable by the immune system, but also as the recruitment of select immune cell populations and/or 
their polarization toward phenotypes that favor cancer growth [26]. For example, among immune cells, 
immunosuppressive T-regulatory cells play a crucial role in tumor progression [27, 28], and remain the 
main obstacle to successful immunotherapy treatment [28]. Tumor-Associated Macrophages (TAMs) are 
also involved in cancer growth, working to establish a mutagenic and cancer-promoting environment 
through their oxidative function, favoring migration of tumor cells through ECM degradation, and 
promoting the formation of new blood vessels for tumor survival through the secretion of angiogenic factors 
[29, 30]. Similarly, Tumor-Associated Neutrophils (TANs) have been found to sustain angiogenesis 
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through the secretion of Vascular Endothelial Growth Factor (VEGF) and Matrix Metalloproteinase-9 
(MMP9) [31-33]. Indeed, infiltration of several immune cell populations into cancers is associated with 
poor outcomes: infiltration of TAMs in mammary tumors is an independent prognostic factor linked to 
lower overall survival [29, 34, 35], tumor recruitment of MMP9+ TANs has been correlated with increased 
angiogenesis and intravasation [32], and systemic removal of Tregs was found to boost natural and vaccine- 
induced anti-tumoral T-cell immunity [27].  
 
Figure 3. MC Infiltration in obese adipose tissue and tumors. (Cozzo, Fuller and Makowski, submitted) 
Our current study focuses on an immune cell subset known as mast cells (MCs), which are a type 
of long-lived myeloid stem cell-derived granulocytes. MCs are traditionally known for their role in 
anaphylaxis, through their release of histamine, heparin and proteases tryptase and chymase, but have also 
recently been associated with processes of wound healing, immune tolerance and angiogenesis [2]. In fact, 
T-cell suppressing-interleukin-10, as well as potently angiogenic and vasculogenic factors VEGF, IL-6 [1] 
and TNFα [36] have all been detected among MC secretions.  These functions make MCs perfect targets of 
tumor recruitment, and recent studies have confirmed that MCs play a pivotal role in the progression of 
malignancies such as breast cancer [1]. Once recruited at the tumor site through the exploitation of the Stem 
Cell Factor (SCF)/cKIT signaling pathway, MCs secrete angiogenic factors and growth factors to support 
vessel formation, thus often accumulating near microvessels, and tumor development. Other MC-specific 
secretions include proteases, such as tryptase and chymase, that activate metalloproteinases for ECM 
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degradation, outward tumor expansion and metastasis [1, 2]. Tryptase-containing MCs are usually found in 
greater numbers on the tumor invasive front and peritumoral tissue, and are associated with higher 
lymphangiogenic and angiogenic microvessel density [2, 37, 38].  MC infiltration remains an independent 
prognostic factor in many cancers, with high MC density predictive of adverse clinical outcomes in human 
colorectal, pancreatic and lung carcinomas, as well as murine pancreatic carcinoma and colon 
adenocarcinoma [2]. It is unknown to what extent MC infiltrate tumors of the breast.  
 
Figure 4. Interaction between a cancer cell and a mast cell in the tumor microenvironment [2]  
Importantly, MC accumulation is characteristic of obesity in both mice and humans [3, 4, 6]. 
Several folds-increase in MC density have been reported in numerous body fat depots including white 
adipose and epididymal fat pad in male mice [3, 4], and white adipose tissue and subcutaneous and omental 
fat pads in male humans [4, 6]. As it is the case in tumors, MCs in adipose tissue were found in association 
with microvessels, suggesting their role in adipose angiogenic modulation [4]. In addition to MC content, 
obesity affects the activation status of MCs, promoting their degranulation and their high secretion levels 
of inflammatory cytokines IL-6, IL-1β and MCP-1 [6]. These findings, and the discovery by Ishijima et al. 
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that MC-deficient cKIT-knockout mice are resistant to diet-induced obesity [39], highlight the role of MCs, 
together with other immune cells, in the promotion of obesity and the maintenance of its characteristic 
smoldering inflammation in adipose depots that may contribute to oncogenesis or tumor progression.  
The dual role played by MCs in the pathogenesis of cancer and obesity suggests that they may 
contribute to the reported association between these two epidemic conditions. This could be especially true 
in the case of high BMI- and high adiposity-correlated carcinomas, such as TNBCs. In both humans and 
mice, breast/mammary adipose is a major body fat depot, in which obesity-induced metabolic changes may 
also activate resident and recruited MCs toward a pro-inflammatory and pro-tumorigenic phenotype. In 
light of this relationship, it is imperative to elucidate the interplay between MC activation and infiltration 
and TNBCs in relation to weight status. Thus, we first hypothesized that obesity increases MC activation 
and infiltration in mammary adipose tissue. We further hypothesized that obesity promotes greater MC 
activation and infiltration into claudin-low breast tumors.  
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METHODS  
Animals and Diet  
This study used data from ongoing pre-clinical studies conducted by Dr. Liza Makowski’s Laboratory at 
the Gillings School of Global Public Health within the University of North Carolina at Chapel Hill (Cozzo 
et al. and Fuller et al., manuscripts in preparation). Animal studies were performed with approval and in 
accordance with the guidelines of the Institutional Animal Care and Use Committee of the University of 
North Carolina at Chapel Hill. Animals were cared for following guidelines established by the Panel on 
Euthanasia of the American Veterinary Medical Association, and in compliance with the Public Health 
Service Policy on Humane Care and Use of Laboratory Animals, which meets the National Institutes of 
Health standards (Guide for the Care and Use of Laboratory Animals, 85-23, 1985). The UNC animal 
facility providing care is AAALAC-approved. UNC also accepts as mandatory the PHS Policy on Humane 
Care and Use of Laboratory Animals and NIH Principles for the Utilization and Care of Vertebrate Animals 
Used in Testing, Research, and Training. Animal studies comply with the ARRIVE guidelines. Mice were 
housed in a climate controlled Department of Laboratory Animal Medicine facility with a 12 h light:dark 
cycle. C57BL/6J and FVB/NJ mouse strains were used in this pilot study. The Slc2a1/GLUT1 floxed 
(GLUTfl/fl) C57BL/6J mouse strain was obtained through collaboration with Dr. Dale Abel (University of 
Iowa, IA). The FVB/NJ strain was obtained from Jackson Laboratories (Bar Harbor, ME). Diets were 
obtained from Research Diets Inc. (New Brunswick, NJ, USA), which provided 10% kcal (“LFD”, 
D12450J) and 60% kcal (“HFD”, D12492) from fat and were matched for proteins, sucrose, vitamins and 
minerals.  
Female mice in the C57BL/6J cohort were weaned onto diet at 3 weeks of age and randomized to either 
LFD or HFD (n=5 on LFD, n=5 on HFD selected for analysis). Animals remained on diet until sacrifice. 
Female mice in the FVB/NJ cohort were randomized to diets at 8 weeks of age (n=7 on LFD, n=8 HFD 
selected for analysis). Additional FVB/NJ mice (n=8 selected for analysis) was started on HFD at 8 weeks 
of age, and were then switched to LFD at 13 weeks of age through the completion of the study.     
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Body Weight and Composition 
 C57BL/6J Cohort 
Body weight was measured prior to starting animals on diet (baseline), and once weekly until sacrifice. 
Body composition including lean mass, fat mass, free water content and total water content of non-
anesthetized mice was measured at week 13, before injection of tumors, using an EchoMRI-100 quantitative 
magnetic resonance whole body composition analyzer (Echo Medical Systems, Houston, TX), as previously 
described [40].  
 FVB/NJ Cohort 
Body weight was measured as above. Body composition was measured at week 8 (baseline), 13 (diet switch, 
DS), 18 (orthotopic transplant) and 21 (sacrifice) as above [40]. 
 
Injection of tumors  
C57BL/6J Cohort 
The murine M-Wnt claudin-low breast cancer cell line was obtained through a collaboration with Dr. 
Stephen Hursting (UNC-Chapel Hill, NC). Features of this cell line, including a CD44+/CD24—-enriched 
profile and high EMT marker expression, have been previously described [5]. Following 10 weeks on diet, 
at 13 weeks of age, animals underwent syngeneic orthotopic transplant of 50,000 M-Wnt cells in 100 μL 
phosphate-buffered saline (PBS) (Sigma Aldrich, St. Louis, MO) directly inoculated into the left 4th 
mammary fat pad. Tumor size was monitored weekly by electronic calipers until sacrifice at the previously 
defined tumor endpoint (tumor diameter 1±0.25 cm in any direction), as described in previous studies [41]. 
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FVB/NJ Cohort 
A luciferase-labeled claudin-low cancer cell line generated from lean C3(1)-TAg mice (referred to as C3-
Tag-luc) was obtained from Dr. William Y. Kim, MD through a collaboration with the Mouse Phase I Unit 
(MP1U, LCCC, Chapel Hill, NC) [42]. At 18 weeks of age, animals in all three diet groups underwent 
orthotopic transplant of 200,000 cells in a 1:1 mixture of high concentration Matrigel® (BD Biosciences, 
Bedford, MA) and Hank’s Buffered Saline Solution (Sigma Aldrich, St. Louis, MO),  into the left 4th 
mammary fat pad. Tumor length and width were measured three times weekly after tumor injection via 
electronic calipers until sacrifice at 21 days of tumor growth. Tumor volumes were calculated as length × 
width2 × 0.5, as previously described [40].  
 
Tissue Harvest  
C57BL/6J Cohort 
Mice were euthanized through carbon dioxide asphyxiation and cervical dislocation. Tumors and the 
contralateral normal mammary fat pads were collected. A portion of each tissue was frozen at -80˚C, and 
another portion was stored in cassettes and formalin-fixed and paraffin embedded (FFPE) for histological 
analysis. Lungs, liver and spleen were also collected.  
FVB/NJ Cohort 
Mice were anesthetized by intraperitoneal injection of avertin (tribromoethanol/amylene hydrate, 1.25%) 
(Sigma Aldich, St. Louis, MO). Blood was collected via cardiac puncture, and cervical dislocation was also 
performed, in accordance with humane euthanasia regulations. Tumors and the contralateral normal 
mammary fat pads were collected. A portion of each tissue sample was frozen at -80˚C, and another portion 
was stored in cassettes and formalin-fixed and paraffin embedded (FFPE) for histological analysis. Lungs, 
liver and spleen were also collected.  
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Histological Analysis 
C57BL/6J Cohort 
Paraffin-embedded tumor and normal mammary fat pad sections collected at 5 μm frequency were mounted 
onto clear-glass slides. Tumor samples in lean and obese groups were size-matched at 1±0.25 cm. Normal 
mammary samples in lean and obese groups were age-matched at 5±0.5 weeks after tumor cell injection. 
Both tumor and normal mammary slides were stained with Toluidine Blue, through the following protocol 
performed by the lab of Dr. Stephen Tilley (UNC-Chapel Hill, NC). Briefly, slides were dewaxed and 
rehydrated with 60% ethyl alcohol, before being exposed to Toluidine Blue O (C.I. 52040) for 1-2 minutes. 
Slides were then rinsed under water and dehydrated twice through exposure to acetone for 1-2 minutes. 
Once stained, slides were scanned into an Aperio Scanscope CS System (Aperio Technologies, Vista, CA. 
USA) at a magnification of 40x. Total tissue area was quantified in mm2 using Aperio Imagescope software 
(Aperio Technologies, Vista, CA. USA). Also using Aperio Imagescope, total mast cell number in each 
slide was manually counted and normalized to total tissue area.   
FVB/NJ Cohort 
Samples for analysis were chosen based on proximity to the median tumor volume of each respective diet 
group. Paraffin-embedded tumor and normal mammary fat pads were sectioned at 5 μm thickness in a serial 
interrupted fashion and mounted onto clear-glass slides. Slides were stained with Toluidine Blue, through 
the aforementioned protocol, and analyzed using Aperio as described above.  
 
Gene Expression 
Gene expression of mast cell-specific Tryptase β-2 was measured using semi-quantitative real-time PCR 
(qPCR). The eukaryotic ribosomal RNA 18S was used as an endogenous control to standardize gene 
expression levels. Tryptase β-2 mRNA expression levels were quantitated using TaqMan Assay-on-
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Demand (AOD) TPSB2 (Thermo Fisher Scientific, Waltham, MA). All reactions had a volume of 10 μL. 
AOD reactions contained 1 μL cDNA, 3.5 μL of deionized water, 5 μL of SsoAdvanced Universal Probes 
Supermix (Bio-Rad Laboratories, Hercules, CA), 0.5 μL 18S and 0.5 μL AOD. Reactions were run at 95°C 
for 10 seconds, then 60°C for 30 seconds for 40 cycles in a using an Applied Biosystems ViiATM 7 Real-
Time PCR System (Thermo Fisher Scientific, Waltham, MA). Data were analyzed using QuantStudio Real-
Time PCR System software (Thermo Fisher Scientific, Waltham, MA) and the comparative ΔΔCT method.  
 
Statistical Analysis  
Data are expressed as mean ± standard error of the mean (SEM). Means were compared as indicated either 
by Student’s t-test, One-way Analysis of Variance (ANOVA) or Two-way ANOVA, with Tukey’s Post 
Hoc Multiple Comparisons testing, using the GraphPad Prism 7 software (GraphPad Software, Inc. La Jolla, 
CA). —P-values < 0.05 are considered statistically significant.  
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RESULTS 
Body Weight and Body Composition 
C57BL/6J Cohort  
At 3 weeks of age, mice were weaned onto either Low Fat Diet (LFD, 10% kcal from fat, n = 5) or High 
Fat Diet (HFD, 60% kcal from fat, n = 5). Between week 16 and 17, mice fed HFD had significantly greater 
body weights than mice fed LFD (P < 0.05, Figure 5a). Body composition was measured by MRI at the 
time of tumor cell injection, and mice on HFD had significantly greater percentages of body fat than mice 
on LFD (P = 0.0028, Figure 5b).  
FVB/NJ Cohort  
At 8 weeks of age, mice were randomized to diet groups: either LFD (10% kcal from fat, n = 7), HFD (60% 
kcal from fat, n = 8), or DS (60%  10% kcal from fat, n=8). Starting at week 10, mice fed HFD had 
significantly greater body weights than mice fed LFD (p < 0.01, Figure 6a) and the trend continued to the 
end of the study (weeks 11 to 21, P < 0.001). At week 13, DS mice were switched to LFD. One week after 
the switch, the body weights of DS group were comparable to the LFD group, and were significantly 
different from mice fed HFD (weeks 14-15, P < 0.01, weeks 16-21, P < 0.0001, Figure 6a).  
Body composition followed a similar trend. At 8 weeks of age, before starting on diet, mice in all 
groups had the same body composition. At week 13, HFD-fed and DS mice had approximately 2-fold 
greater body fat percentages than mice fed LFD (P < 0.0001, Figure 6b). After being switched to LFD, the 
body composition of mice in the DS group returned to the LFD baseline: at weeks 18 and 21, the percentage 
body fat of mice in the DS group was found to be significantly different from the mice on HFD (P < 0.0001, 
Figure 6b). 
Within the subset of mice selected for mast cell analysis in this pilot study, mice fed HFD also showed 
increased tumor volumes with respect to LFD-fed mice and DS mice (P < 0.01 HFD vs. LFD/DS, Figure 
7A).  
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Figure 5. C57BL/6J mice on HFD experienced significant weight gain and increased percentage body 
fat. (A) Body weight (g) was measured weekly from 3 weeks of age until sacrifice for low fat diet (LFD, 
n=5) and high fat diet (HFD, n=5) groups. * P < 0.05 for weeks 16-17 HFD vs. LFD. (B) Body composition 
(g fat mass/g body weight) from MRI was obtained at week 13 upon injection of tumor cells. * P = 0.0028 
HFD vs. LFD. 
 
 
Figure 6. FVB/NJ mice fed HFD experienced significant weight gain and increased percentage body 
fat, while Diet Switch mice experienced body weight and fat loss and returned to LFD baseline. (A) 
Body weights (g) was measured weekly from 8 weeks of age until sacrifice for LFD (n=7), HFD (n=8) and 
DS (n=8) groups. ** P < 0.01 for week 10, LFD vs. HFD. **** P < 0.0001 for weeks 11-21, LFD vs. HFD. 
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+++ P < 0.001 for weeks 10, LFD vs. DS. ++++ P < 0.0001 for weeks 11-13, LFD vs. DS. ^^ P < 0.01 for 
weeks 14-15, DS vs. HFD. ^^^^ P < 0.0001 for weeks 16-21, DS vs. HFD. (B) Body adiposity (% body 
fat) was measured at four different time points: baseline, DS, orthotopic injection, and sacrifice. **** P < 
0.0001 LFD vs. HFD. ++++ P < 0.0001 LFD vs. DS. ^^^^ P < 0.0001 DS vs. HFD.  
 
 
Figure 7. In the original FVB/NJ cohort, HFD exposure accelerated tumor progression. Tumor 
volume (mm3) was measured from orthotopic transplant to sacrifice 3 weeks later as length × width2 × 0.5. 
*P < 0.01 LFD vs. HFD. *** P = 0.001 LFD vs. HFD. ^ P < 0.05 HFD vs. DS. ^^ P = 0.009 HFD vs. DS.   
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Mast Cell Density  
C57BL/6J 
Mast cell density in both normal mammary tissue and tumors of C57BL/6J mice was reported as number 
of toluidine blue-positive cells per mm2 of tissue. Mast cell density trended toward lower values in normal 
mammary tissue of mice on HFD as compared with mice on LFD, but the difference was not significant 
(Figure 8a). A non-significant increase was also seen in claudin-low tumors, with mice in the HFD group 
presenting slightly higher mast cell density than mice in the LFD group (Figure 8b). A comparison of mast 
cell densities across tissue types by two-way analysis of variance (ANOVA) indicated the presence of a 
tissue effect, with mast cell density of normal mammary tissue significantly greater than that of tumors (P 
= 0.037, Figure 8c). No diet effect was detected.      
  
 
(NM) 
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Figure 8. Comparison of Mast Cell Density between HFD and LFD groups in normal mammary and 
tumor tissues of C57BL/6J mice. (A) Mast cell density (cells/mm2) in normal mammary tissue was 
measured. (B) Mast cell density (cells/mm2) in claudin-low tumors was measured (C) Mast cell densities 
were compared across diet groups and tissue types. P = 0.037 NM vs. tumor by two-way ANOVA.  
 
FVB/NJ 
Mast cell density in both normal mammary tissue and tumors of FVB/NJ mice was reported as number of 
toluidine blue-positive cells per mm2 of tissue. Mast cell density trended toward elevated in normal 
mammary tissue of mice in the DS as compared with mice on HFD or LFD, but the difference was not 
significant (Figure 9a). A similar trend was also seen in claudin-low tumors (Figure 9b). A comparison of 
mast cell densities across tissue types by two-way ANOVA indicated the presence of a tissue effect, with 
mast cell density of tumors significantly greater than that of normal mammary (P = 0.039, Figure 9c), as 
well as a diet effect (P = 0.033, Figure 9c).  
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Figure 9. Comparison of Mast Cell Density between HFD, LFD and DS groups in normal mammary 
and tumor tissues of FVB/NJ mice. (A) Mast cell density (cells/mm2) in normal mammary tissue was 
non-significant by diet (P = 0.054 by one-way ANOVA). (B) Mast cell density (cells/mm2) in claudin-low 
tumors was measured. (C) Mast cell densities were compared across diet groups and tissue types. *P = 
0.039 NM vs. tumor by two-way ANOVA. P = 0.033 for diet effect by two-way ANOVA.  
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Figure 10. Representative photomicrographs of Toluidine Blue-stained Mast Cells in Normal 
Mammary Tissue. (A-B) Detail of toluidine blue-positive MCs (scale bar = 100 μm) in Normal Mammary 
adipose tissue of C57BL/6J mouse, highlighting degranulation (arrows). (C) Toluidine blue-positive MCs 
(scale bar = 100 μm) associated with blood vessels (*) and lymphatic vessels. (D-E) Toluidine blue-positive 
MCs (scale bar = 100 μm) associated with mammary ducts (†).  
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Figure 11. Representative photomicrographs of Toluidine Blue-stained Mast Cells in Claudin-Low 
Breast Tumors. (A) Pattern of MC infiltration in Claudin-Low tumors (scale bar = 100 μm). (B-C) Detail 
of toluidine blue-positive MCs (scale bar = 50 μm), including degranulation.  
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Tryptase β-2 Gene Expression 
C57BL/6J  
A nonsignificant trend toward increased Tryptase ß-2 expression in HFD-fed mice was observed in both 
normal mammary tissue and claudin-low tumors (Figure 12a-b), with borderline significance in normal 
mammary (P = 0.055, Figure 12a). However, a comparison of gene expression levels across diet and tissue 
types by two-way ANOVA indicated the presence of both a tissue effect, with Tryptase ß-2 expression 
significantly higher overall in normal mammary tissue than in tumors (P = 0.026, Figure 12c), and a diet 
effect, with Tryptase ß-2 expression higher overall in mice fed HFD than LFD (P = 0.035, Figure 12c).       
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Figure 12. Comparison of Tryptase ß-2 expression between LFD and HFD groups in normal 
mammary and tumor tissue of C57BL/6J mice. (A) Tryptase ß-2 expression was measured by qPCR in 
LFD-fed and HFD-fed mice. (B) Tryptase ß-2 expression in LFD-fed and HFD-fed mice did not 
significantly differ (P = 0.56 by Student’s t-test). (C) Tryptase ß-2 fold expression levels were compared 
across diet groups and tissue types. P = 0.035 a (LFD) vs b (HFD). * P = 0.026 NM vs. tumor by two-way 
ANOVA.  
 
FVB/NJ 
Expression levels of mast-cell specific Tryptase ß-2 were significantly elevated in HFD-fed mice as 
compared to DS mice (*P = 0.017, Figure 13a), with a trend toward increased expression relative to LFD-
fed mice (P=0.063). Tryptase ß-2 expression levels in tumors did not significantly differ by diet (Figure 
13b). However, a comparison of gene expression levels across diet and tissue types indicated the presence 
of both a tissue effect and a diet effect. A Tukey’s Post Hoc multiple comparisons analysis following two-
way ANOVA revealed a significant difference between the HFD and LFD groups (P = 0.025, Figure 13c), 
and between HFD and DS groups (P = 0.0024, Figure 13c) in normal mammary.  
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Figure 13. Comparison of Tryptase ß-2 expression between LFD, HFD and DS groups in normal 
mammary and tumor tissue of female FVB/NJ mice. (A) Tryptase ß-2 expression was significantly 
greater in normal mammary tissue of mice fed HFD vs. DS. (*P = 0.017 by one-way ANOVA). (B) No 
significant difference between Tryptase ß-2 expression of HFD, LFD and DS groups was observed in 
tumors. (C) Tryptase ß-2 expression levels were compared across diet groups and tissue types. *P = 0.025 
NM HFD vs. LFD. **P = 0.0024 NM HFD vs. DS by two-way ANOVA.  
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DISCUSSION 
 This pilot study aimed at examining the effects of obesity on MC infiltration and activation within 
normal mammary tissue and claudin-low breast tumors in mice. Obesity, an epidemic condition in the 
United States, is a risk factor for a number of diseases, including triple negative breast cancer. The study 
design first tested the hypothesis of increased mast cell density and/or activation in obesity using the 
FVB/NJ mouse strain. Female mice fed HFD did present greater weight gain and percent body adiposity 
than mice fed LFD. However, despite being maintained on diets for several weeks, differences in adiposity 
between LFD-fed and HFD-fed C57BL/6J mice in this study were not as stark as expected. Perhaps for this 
reason, there were no statistically significant differences in MC density, a measure of MC infiltration, 
observed between HFD-fed and LFD-fed mice in tissue-specific analyses using Student’s t-tests. On the 
other hand, a comparison across tissue and diet types using two-way ANOVA revealed an overall 
significant tissue effect, with normal mammary fat pads containing greater MC counts than tumors. MC 
activation was measured through the quantification of MC-specific protease tryptase β-2 (Appendix A). 
Remarkably, although obesity did not significantly affect MC density, obesity-induced alterations in the 
mammary fat pad and tumor microenvironments appear to have promoted a change toward an activated 
phenotype in the MCs present in these tissues. While no significant difference in tryptase mRNA levels 
was observed between HFD-fed and LFD-fed mice in tissue specific analyses, a two-way ANOVA showed 
that overall, HFD-fed mice presented higher tryptase mRNA levels than LFD-fed mice, regardless of tissue 
type. The analysis also revealed the presence of a significant tissue effect, with normal mammary tissue 
presenting higher tryptase β-2 levels than tumors, thus mirroring trends in MC density.  
 The results from this portion of the study deviated from our hypothesis, as we did not see changes 
in obesity-induced MC infiltration in either normal mammary fat pads or tumors of C57BL/6J mice. A 
significant departure from previous literature was our observation that the traditionally obesogenic 
C57BL/6J mice did not gain as much weight and adiposity when fed HFD as expected. Such finding may 
be ascribed to the effects of age at diet start on weight gain, as evidence suggests that post-weaning HFD 
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start at 6-10 weeks of age is more successful at inducing maximum weight gain in mice than weaning onto 
diet [43]. Moreover, the data set utilized in this analysis was limited in size and presented high variability. 
Based on preliminary data, we were able to conduct a statistical power analysis revealing that, given the 
standard deviations reported, to detect a difference in mean MC density by diet in tumors, an N of 80 for 
each diet group would have been required to achieve 80% power with a Type I error rate (α) of 0.05. To 
observe a difference between diet groups in normal mammary tissue, using the same statistical parameters, 
an N of 46 per diet group would have been required.  
 The results on MC activation from our C57BL/6J mice remained encouraging, so we decided to 
test our hypothesis on a different mouse strain. We repeated our analysis using an FVB/NJ cohort. As for 
the BL/6J cohort, female mice fed HFD presented greater weight gain and body percent adiposity than mice 
fed LFD. The DS was successful at reversing both weight and adiposity gain, as mice in this group first 
gained as much weight and body fat as HFD-fed mice, then returned to the LFD-fed mice baseline upon 
transition from HFD to LFD.  Moreover, HFD exposure accelerated tumor progression, measured as change 
in tumor volume from injection to sacrifice, an observation that corroborates previous findings from our 
lab on the effects of obesity on tumor growth [40, 44]. In FVB/NJ mice, tissue specific analyses of MC 
density by one-way ANOVA also did not reveal any significant difference between diet groups; however, 
a comparison across tissue and diet types by two-way ANOVA showed both significant tissue and 
significant diet effects. Interestingly, the tissue effect was reversed with respect to the BL/6 mice, as tumors 
were found to have higher MC density than normal mammary. Because the FVB/NJ arm of the study had 
a greater N and thus greater statistical power, it is plausible that these results, as opposed to the C57BL/6J 
ones, more accurately reflect mast cell infiltration in normal mammary versus tumors. As for the diet effect, 
the statistical analysis did not yield clear results regarding which diet group presented a significantly 
different MC density. Interestingly, the DS group presented greater variability than the LFD and HFD 
groups in both tissue types, with standard deviations of 9.38 in normal mammary and 23.41 in tumors which 
were much greater than the other diet groups. Importantly, tryptase β-2 mRNA levels were not significantly 
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different between diet groups in claudin-low tumors of FVB/NJ mice, but they were in normal mammary 
fat pads. Indeed, normal mammary tissue of HFD-fed mice had significantly higher tryptase mRNA levels 
than both LFD-fed mice and mice in the DS group. In addition to the observed difference between HFD 
and LFD groups, the similarities in protease expression between the LFD and DS were particularly 
insightful, as our results suggest that weight loss may promote a reversal in the activation state of fat pad-
infiltrating mast cells.     
 Findings from the FVB/NJ cohort of our study were very promising, as they largely 
corroborated our results from the BL/6J cohort, which showed that obesity influences MC activation in 
normal mammary tissue. However, we were not able to confirm our hypothesis in claudin-low tumors, as 
no increase in MC activation or density was observed upon HFD exposure. These results could be due to a 
number of factors, including our limited sample size with high variability that did not allow us to detect 
subtle differences between diet groups. Moreover, the orthotopic transplant model of cancer used in this 
pilot study included an intrinsic limitation in that it bypasses early carcinogenesis stages, such as pre-
neoplastic lesions formation, and that it does not allow for the establishment of a strong tumor 
microenvironment. It might be that early stages of tumor development are critical in the recruitment and 
activation of MCs, which may thus play a more important role in the etiology of breast cancer, rather than 
its progression.  
  
 36 
Conclusion 
The body of literature on mast cell infiltration of fat depots and tumors suggests that, upon 
conditions of obesity, many body adipose depots, such as visceral and subcutaneous, and a number of 
cancers, namely pancreatic, colorectal and lung carcinomas, experience elevated MC infiltration and 
activation [2]. Although our study was not able to confirm increased MC infiltration and activation in 
claudin-low breast tumors, our findings suggested an obesity-induced MC activation effect in normal 
mammary tissue. Increased tryptase β-2 levels upon HFD exposure were observed independently of MC 
density, suggesting that HFD might activate MCs toward a pro-inflammatory phenotype, independently 
from MC counts. Importantly, these results were reproducible in two mouse strains and two cancer cell 
lines.  
Moreover, the increased MC activation in normal mammary tissue upon HFD exposure occurred 
in concomitance with an increase in tumor progression given the same dietary conditions, suggesting that 
MC activation in obese normal mammary tissue may have implications for potentially influencing tumor 
progression. In a similar fashion, DS was successful at reversing both tryptase β-2 levels and tumor 
progression back to the LFD-baseline. These results corroborated findings from previous studies by our 
group, whereby we showed that diet switch-induced weight loss prior to tumor latency can reverse tumor 
progression and improve TNBC-promoting metabolic risk factors [40]. In humans, low fat dietary 
interventions in post-menopausal women with a primary early stage breast cancer diagnosis were also 
shown to improve relapse-free survival, although these results were not seen in post-menopausal women 
without prior breast cancer [45, 46].  
In order to examine the implications of MC-dependent modulation of obesity and cancer, future 
studies could confirm the degree of MC infiltration and activation observed upon HFD exposure through a 
quantification of MC density through more sensitive cell detection methods, such as flow cytometry, and 
through the measurement of other MC-specific markers of activation, such as the protease chymase [2]. 
Moreover, because of the intrinsic limitations of the orthotopic transplant model of breast cancer, as 
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mentioned in the discussion above, MC infiltration and activation should be studied in spontaneous models 
of breast cancer, such as the C3(1)-Tag mouse strain, in order to examine the effects of early carcinogenesis 
stages in the recruitment and activation of MCs. Finally, an interesting extension of the current study would 
explore location-specific MC infiltration and activation, as the literature suggests that peritumoral MC 
density, as opposed to intratumoral, is associated with worse prognosis, but the evidence is inconclusive 
[2].  
In all, our study highlights the need to expand the body of research on the role of immune cells, 
especially mast cells, in the development and maintenance of breast malignancies in the context of obesity. 
Our pilot study adds mast cells to a growing list of pro-inflammatory and pro-tumorigenic immune cell 
lineages that may be influenced by the obese mammary milieu, and thus underscore the importance of 
further research regarding mast cells in the pathogenesis of both obesity and claudin-low breast cancer. 
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APPENDICES  
Appendix A: In silico analysis of TPSB2 specificity to Mast Cells (from biogps.com)    
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